Jones Robert, Ryan Mary, Friedlander Michael
Department of Medical Oncology, Prince of Wales Hospital, High Street, Randwick NSW 2031, Australia.
Gynecol Oncol. 2003 Apr;89(1):112-5. doi: 10.1016/s0090-8258(03)00066-0.
This aim of this study was to investigate the feasibility of re-treating patients who had experienced a hypersensitivity reaction to carboplatin with cisplatin following desensitisation.
Five patients with recurrent ovarian cancer who had a previous documented hypersensitivity reaction to carboplatin and a good clinical indication for continuing treatment with platinum were retreated following cisplatin desensitisation. All patients were rechallenged with cisplatin following a prolonged desensitisation protocol and the initial four patients then received subsequent cycles with a shortened protocol in an attempt to simplify and shorten the procedure.
All five patients tolerated their first cycle of cisplatin on rechallenge using the full desensitisation protocol with no adverse reactions. Two patients received further treatments (one and three cycles) with a shortened protocol but treatment was terminated due to further adverse hypersensitivity reactions. Two patients received one further cycle with a shortened protocol and did not experience problems with hypersensitivity but treatment was stopped due to evidence of disease progression One patient received a further two cycles using the full desensitisation protocol without problems but treatment was stopped due to evidence of disease progression.
A full cisplatin desensitisation protocol appears to be an effective way to re-treat patients who have previously experienced a hypersensitivity reaction to carboplatin. Attempts to shorten the procedure were associated with further allergic reactions, suggesting that the full protocol should be followed with each treatment.
本研究的目的是探讨对卡铂发生过敏反应的患者在脱敏后用顺铂重新治疗的可行性。
5例复发性卵巢癌患者既往有对卡铂过敏反应的记录,且有继续铂类治疗的良好临床指征,在顺铂脱敏后进行重新治疗。所有患者按照延长的脱敏方案用顺铂再次激发,最初4例患者随后采用缩短的方案接受后续疗程,以试图简化和缩短该过程。
所有5例患者在使用完整脱敏方案再次激发时均耐受了他们的第一个顺铂周期,无不良反应。2例患者采用缩短方案接受了进一步治疗(1个和3个周期),但由于进一步的过敏不良反应而终止治疗。2例患者采用缩短方案又接受了1个周期,未出现过敏问题,但由于疾病进展的证据而停止治疗。1例患者使用完整脱敏方案又接受了2个周期,无问题,但由于疾病进展的证据而停止治疗。
完整的顺铂脱敏方案似乎是重新治疗既往对卡铂发生过敏反应患者的有效方法。试图缩短该过程与进一步的过敏反应相关,这表明每次治疗都应遵循完整方案。